[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Indexing Sources::
Guide for Authors::
Online Submission::
Articles archive::
For Reviewers::
Contact us::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Feyz style for Endnote
Feyz style for Endnote
Please download the style and copy as following:
C:Program Files (x86)/EndNote X8/Styles
:: Volume 19, Issue 5 (Bimonthly 2015) ::
Feyz 2015, 19(5): 438-445 Back to browse issues page
Hyperphosphatemia among patients with chronic kidney disease
Seyyed seifollah Beladi-Mousavi , Zahra Chitsazian * , Fatemeh Hayati , Shokoh Shayanpour , Gholam Reza Alizadeh-Atar
Kashan University of Medical Sciences , z_chitsazian@yahoo.com
Abstract:   (4649 Views)

Background: Hyperphosphatemia alone or in combination with hypercalcemia has been associated with increased mortality and morbidity among patients with chronic kidney disease (CKD). The present study aimed to review some of published articles about treatment of hyperphosphatemia among patients with CKD.

Materials and Methods: To collect the current data, many articles were reviewed in a variety of sources such as PubMed, Scopus, Current Content, Embase, and IranMedex with keywords of "hyperphosphatemia" and "chronic kidney disease". Only articles published in English language, as full-text manuscripts, were included in this article.

Results: Common treatment of hyperphosphatemia among patients with CKD is dietary phosphate restriction and administration of phosphate binders to block absorption of ingested phosphate from the intestine. Phosphate restriction should primarily include unnecessary dietary phosphate (as many processed foods, colas, dairy products and certain vegetables). Phosphate-binding agents are categorized as calcium-containing phosphate binders (calcium carbonate and calcium acetate) and noncalcium-containing phosphate binders (sevelamer and lanthanum). All of phosphate-binding agents are effective in lowering serum phosphate however, noncalcium-containing phosphate binders are preferred among hypercalcemic patients, normocalcemic patients who also received vitamin D analogs, patients with vascular calcification and patients with adynamic bone disease.

Conclusion: There is a concern about safety of calcium-containing binders for long-term use and these agents may be associated with hypercalcemia, vascular calcification and adynamic bone disease.

Keywords: Chronic kidney disease, Hyperphosphatemia, Treatment
Full-Text [PDF 199 kb]   (8355 Downloads)    
Type of Study: Research | Subject: General
Received: 2015/12/23 | Revised: 2015/12/23 | Accepted: 2015/12/23 | Published: 2015/12/23
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Beladi-Mousavi S S, Chitsazian Z, Hayati F, Shayanpour S, Alizadeh-Atar G R. Hyperphosphatemia among patients with chronic kidney disease. Feyz 2015; 19 (5) :438-445
URL: http://feyz.kaums.ac.ir/article-1-2867-en.html

Creative Commons License
This open access journal is licensed under a Creative Commons Attribution-NonCommercial ۴.۰ International License. CC BY-NC ۴. Design and publishing by Kashan University of Medical Sciences.
Copyright ۲۰۲۳© Feyz Medical Sciences Journal. All rights reserved.
Volume 19, Issue 5 (Bimonthly 2015) Back to browse issues page
مجله علوم پزشکی فیض Feyz Medical Sciences Journal
Persian site map - English site map - Created in 0.05 seconds with 47 queries by YEKTAWEB 4624